A 68-year-old man from Delhi presents with progressive lower urinary tract symptoms for 8 months. He complains of nocturia (4–5 times per night), weak urinary stream, hesitancy, and incomplete emptying. He denies hematuria, fever, or weight loss. Digital rectal examination reveals a smooth, firm, symmetrically enlarged prostate. Post-void residual urine is 120 mL. Serum PSA is 2.8 ng/mL (normal). Uroflowmetry shows a peak flow rate of 8 mL/s. What is the most appropriate next step in management?

Explanation

## Clinical Assessment of BPH Severity **Key Point:** This patient has moderate symptomatic BPH with objective evidence of outlet obstruction (reduced peak flow 8 mL/s, elevated post-void residual 120 mL) but no acute retention or renal impairment. ### Management Algorithm for Symptomatic BPH ```mermaid flowchart TD A[Symptomatic BPH confirmed]:::outcome --> B{Severity assessment}:::decision B -->|Mild symptoms| C[Watchful waiting + lifestyle modification]:::action B -->|Moderate symptoms| D[Alpha-blocker first-line]:::action B -->|Severe symptoms or complications| E[Consider combination therapy or TURP]:::action D --> F[Assess response at 4-6 weeks]:::decision F -->|Good response| G[Continue alpha-blocker]:::outcome F -->|Inadequate response| H[Add 5-alpha reductase inhibitor]:::action E --> I[TURP if refractory or acute retention]:::action ``` ### Why Alpha-Blocker is First-Line **High-Yield:** Alpha-blockers (tamsulosin, alfuzosin, doxazosin) relax smooth muscle in the prostate and bladder neck, providing rapid symptomatic relief within 1–2 weeks. They are the **first-line pharmacotherapy** for moderate LUTS due to BPH [cite:Harrison 21e Ch 297]. **Clinical Pearl:** This patient's peak flow of 8 mL/s (normal >15 mL/s) and PVR of 120 mL confirm obstruction but do not mandate surgery. Medical management should be attempted first unless there is acute retention, recurrent UTI, or renal dysfunction. ### Why Not Immediate TURP? - TURP is reserved for **refractory cases** (failure of medical therapy after 4–6 weeks), acute retention, recurrent UTI, or large glands (>45 g). - This patient has not yet received medical therapy. ### Why Not 5-Alpha Reductase Inhibitor Monotherapy? - 5-alpha reductase inhibitors (finasteride, dutasteride) take **3–6 months** to show effect and are slower than alpha-blockers. - They are best used as **add-on therapy** in patients with large prostates (>30 g) or inadequate response to alpha-blockers alone. ### Why Not Urodynamic Studies? - Urodynamics are **not routine** in uncomplicated BPH. They are reserved for diagnostic uncertainty (e.g., suspected detrusor dysfunction, mixed incontinence, or failed TURP). **Mnemonic:** **TURP Indications = RARE** - **R**efractory to medical therapy (4–6 weeks trial) - **A**cute retention (recurrent) - **R**ecurrent UTI or hematuria - **E**levated PVR with renal impairment